Cunita
Cunita Uses, Dosage, Side Effects, Food Interaction and all others data.
Cunita is a gastroprokinetic agent and antiulcer benzamide with agonist activity at 5-HT1 and 5-HT4 receptors and antagonist activity at 5-HT2 receptors. It is marketed in Spain and Mexico.
| Trade Name | Cunita |
| Generic | Cinitapride |
| Cinitapride Other Names | Cinitaprida, Cinitapride, Cinitapridum |
| Type | Tablet |
| Formula | C21H30N4O4 |
| Weight | Average: 402.4873 Monoisotopic: 402.226705468 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | Cubit Healthcare |
| Available Country | India |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Cunita is a benzamide with gastroprokinetic and antiemetic properties typically used for the treatment of gastrointestinal motility disorders such as gastroesophageal reflux disease (GERD), non-ulcer dyspepsia, and delayed gastric emptying.
It is indicated to treat gastrointestinal disorders associated with motility disturbances like gastroesophageal reflux disease (GERD), non-ulcer dyspepsia and delayed gastric emptying.
Cunita is also used to associated treatment for these conditions: Dyspepsia, Flatulence, Gastro-esophageal Reflux Disease (GERD), Gastroesophageal Reflux, Decreased gastrointestinal motility, Meteorism, Mild Dyspepsia, Moderate Dyspepsia
How Cunita works
Cunita is a substituted benzamide with 5-HT receptor antagonist and agonist activity.
Toxicity
The symptoms of overdose include drowsiness, confusion and extrapyramidal effects.
Elimination Route
The absorption of cinitapride (12mg) following oral administration was rapid, with peak levels being achieved 2 h after dosing; absorption following intramuscular administration (4mg) was even more rapid, with peak levels (50% more that oral levels) being achieved 1 h after dosing.
Half Life
3-5 h during the first 8 h and a residual half-life greater than 15 h thereafter.
Innovators Monograph
You find simplified version here Cunita
